High Expression of Y-Box-Binding Protein-1 is Associated with Poor Survival in Resectable Esophageal Squamous Cell Carcinoma

详细信息    查看全文

• 作者：Yong Li MD (1) (2)
  Zhe-Sheng Wen MD (1) (2)
  Hao-Xian Yang MD (1) (2)
  Rong-Zhen Luo MD (3)
  Ying Zhang MD (2)
  Mei-Fang Zhang MD (3)
  Xin Wang MD (1) (2)
  Wei-Hua Jia PhD (2)
  
• 刊名：Annals of Surgical Oncology
• 出版年：2011
• 出版时间：November 2011
• 年：2011
• 卷：18
• 期：12
• 页码：3370-3376
• 全文大小：2003KB
• 参考文献：1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. / CA Cancer J Clin. 2010;60:277-00. CrossRef
  2. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. / J Gastroenterol Hepatol. 2009;24:729-5. CrossRef
  3. Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I, et al. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. / World J Surg. 2009;33:1002-. CrossRef
  4. Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. / Int J Clin Oncol. 2008;13:474-. CrossRef
  5. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CD, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. / J Clin Oncol. 2008;26:1086-2. CrossRef
  6. Enzinger PC, Mayer RJ, Esophageal cancer. / N Engl J Med. 2003;349:2241-2. CrossRef
  7. Evdokimova VM, Ovchinnikov, LP. Translational regulation by Y-box transcription factor: involvement of the major mRNA-associated protein, p50. / Int J Biochem Cell Biol. 1999;31:139-9. CrossRef
  8. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. / Bioessays. 2003;25:691-. CrossRef
  9. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. / Cancer Res. 2005;65:4078-7. CrossRef
  10. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, et al (2009) Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. / Cancer Cell. 15: 402-5. CrossRef
  11. Mouneimne G, Brugge JS. YB-1 translational control of epithelial-mesenchyme transition. / Cancer Cell. 2009;15:357-. CrossRef
  12. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. / Clin Cancer Res. 2001;7:3151-5.
  13. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. / J Pathol. 2003;199:251-. CrossRef
  14. Gimenez-Bonafe P, Fedoruk MN, Whitore TG, Akbari M, Ralph JL, Ettinger S, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. / Prostate. 2004;59:337-9. CrossRef
  15. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, et al. Co-expression of Y box-binding protein 1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. / Gynecol Oncol. 2004;93:287-1. CrossRef
  16. Huang JX, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein,YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. / Int J Oncol. 2005;26:607-3.
  17. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, et al (2005) The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. / Clin Cancer Res. 11: 7354-1. CrossRef
  18. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. / Mod Pathol. 2009;22:282-0. CrossRef
  19. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. / Ann Surg Oncol. 2010;17:1721-. CrossRef
  20. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. / J Clin Pathol. 2000;53:125-0. CrossRef
  21. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. / Clin Cancer Res. 1998;4:2273-.
  22. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, et al. YB-1 as cell cycle regulated transcription factor facilitating cyclic A and cyclin B1 gene expression. / J Biol Chem. 2003;278:27988-6. CrossRef
  23. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. / FEBS Lett. 1997;417:390-. CrossRef
  24. Zhang YF, Homer C, Edwards SJ, Hananeia L, Lasham A, Royds J, et al. Nuclear localization of Y-box factor YB1 requires wild-type p53. / Oncogene. 2003;22:2782-4. CrossRef
  25. Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, et al (2009) Nuclear detection of Y-box protein-1 YB-1 closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. / BMC Cancer 9: 410. CrossRef
  26. Bader AG, Vogt PK. An essential role for protein synthesis in oncogenic cellular transformation. / Oncogene. 2004;23:3145-0. CrossRef
  27. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. / Nat Rev Cancer. 2002;2:489-01. CrossRef
  28. Bader AG, Vogt PK. Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. / Mol Cell Biol. 2005;25:2095-06. CrossRef
  29. Bader AG, Felts KA, Jiang N, Chang HW, Vogt PK. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. / Proc Natl Acad Sci U S A. 2003;100:12384-. CrossRef
  30. Cobbold LC, Spriggs KA, Haines SJ, Dobbyn HC, Hayes C, de Moor CH, et al. Identification of IRES-trans-acting factors for the Myc family of IRESs. / Mol Cell Biol. 2007;28:40-. CrossRef
  
• 作者单位：Yong Li MD (1) (2)
  Zhe-Sheng Wen MD (1) (2)
  Hao-Xian Yang MD (1) (2)
  Rong-Zhen Luo MD (3)
  Ying Zhang MD (2)
  Mei-Fang Zhang MD (3)
  Xin Wang MD (1) (2)
  Wei-Hua Jia PhD (2)
  
  1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People’s Republic of China
  2. State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People’s Republic of China
  3. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People’s Republic of China
  

文摘

Background Y-box-binding protein-1 (YB-1) is a multifunctional protein that regulates gene expression through both transcriptional and translational mechanism. Its expression has been associated with tumor progression and poor prognosis of many cancers. However, its role and clinical significance in resectable esophageal squamous cell carcinoma (ESCC) is still scanty. The purpose of this study was to investigate the prognostic significance of YB-1 expression by immunohistochemistry in a group of patients with ESCC treated with surgical resection. Methods Tissue microarray that included 233 surgically resected ESCC specimens and 49 cases of adjacent normal tissues was successfully generated for immunohistochemical evaluation. The clinical/prognostic significance of YB-1 expression was statistically analyzed. Kaplan–Meier analysis was used to compare the postoperative survival between groups. Results The results showed the immunostaining of YB-1 was distributed predominantly in cytoplasm in tumor cells, which occurred in all of the 233 patients. A higher recurrence (disease-free survival) and lower survival (overall survival) of ESCC was found in patients whose tissues had increased YB-1 expression (P?<?.001/P?=?.001). Furthermore, YB-1 expression could stratify the patient survival (disease-free survival/overall survival) in stage II (P?=?.012/.016). The Cox proportionate hazard regression model also established that high YB-1 expression was significantly correlated with increased risk (RR?=?1.752) of recurrence compared with lowYB-1 expression (P?=?.004). Conclusions High expression of YB-1 is associated with poor survival in resectable ESCC patients.